BioMarin Pharmaceutical Inc (NASDAQ:BMRN)
| 65.55 Data as of May 22 |  +0.55 / +0.85%Today’s Change | 34.30 Today|||52-Week Range 71.56 | +33.23% Year-to-Date |
Latest BMRN News | Press Releases
| Cramer's 'Mad Money' Recap: Think Dividends, Not Coupons May 20 / TheStreet.com | Biomarin Stock Falls On Unusually High Volume (BMRN) May 16 / TheStreet.com |
Today’s Trading
| Previous close | 65.00 |
| Today’s open | 65.67 |
| Day’s range | 64.94 - 69.79 |
| Volume | 2,177,889 |
| Average volume (3 months) | 1,330,236 |
| Market cap | $9.0B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/22/2013
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -37.06% |
| Earnings growth (next 5 years) | +36.00% |
| Revenue growth (last year) | +10.96% |
| P/E ratio | NM |
| Price/Sales | 11.96 |
| Price/Book | 8.05 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| FRXForest Laboratories ... | -0.41 | -1.08% |
| PRGOPerrigo Co | -0.58 | -0.49% |
| ONXXOnyx Pharmaceuticals... | +0.12 | +0.13% |
| RDYDr.Reddy's Laborator... | +0.66 | +1.79% |
Data as of 4:04pm ET, 05/22/2013
Financials
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | -$0.29 |
| Annual revenue (last year) | $494.9M |
| Annual profit (last year) | -$114.3M |
| Net profit margin | -23.11% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Jean-Jacques Bienaimé, MBA |
Chief Financial Officer & Executive Vice President Daniel K. Spiegelman, MBA |
Corporate headquarters San Rafael, California |
Forecasts
